J&J(JNJ)
Search documents
Court Orders Johnson & Johnson And Kenvue To Pay $45 Million In Talcum Baby Powder Lawsuit
Forbes· 2024-04-20 19:25
ToplineAn Illinois court late Friday ordered pharmaceutical giant Johnson & Johnson and Kenvue to pay $45 million to a family that alleged the companies’ talcum-based baby powder led to the death of a relative diagnosed with a fatal cancer linked to asbestos exposure, the company’s latest legal issue involving talc products.Friday’s ruling in Illinois came a day after a judge in Florida rejected similar claims. Getty Images Key FactsTheresa Garcia died in July 2020 after being diagnosed with mesothelioma, a ...
Investing for the Long-Term: 3 Stocks With Proven Track Records
InvestorPlace· 2024-04-20 10:37
With continued volatility in the stock market right now, it’s no wonder investors are looking for stocks with proven track records to bolster their portfolios. While U.S. stocks opened strong on Monday after a concerning ending to the prior week, investors are still uneasy about the current state of the market. Tensions in the Middle East, concerns that the Federal Reserve may not reduce interest rates as fast as previously hoped and fears over continued inflation are still top of mind for many investors ri ...
Johnson & Johnson Amplifies MedTech Profile in Q1 Earnings
PYMNTS· 2024-04-16 17:07
Johnson & Johnson (J&J) has emphasized the pivotal role of medical technology (MedTech) in advancing healthcare.During a Tuesday (April 16) call with analysts to discuss the first quarter (Q1) and full-year 2023 financial results, the pharmaceutical giant underscored its commitment to bolstering its reputation as an “innovation powerhouse.” A significant move in this direction is the acquisition of Shockwave Medical, with an enterprise value of approximately $13.1 billion. According to the company, the purc ...
J&J(JNJ) - 2024 Q1 - Earnings Call Transcript
2024-04-16 16:19
Johnson & Johnson (NYSE:JNJ) Q1 2024 Earnings Conference Call April 16, 2024 8:30 AM ET Company Participants Jessica Moore - VP, IR Joaquin Duato - Chairman & CEO Joseph J. Wolk - EVP & CFO Jennifer L. Taubert - EVP, Worldwide Chairman, Innovative Medicine Timothy Schmid - EVP, Worldwide Chairman, MedTech John C. Reed - EVP, Innovative Medicine, R&D, Johnson & Johnson Conference Call Participants Terence Flynn - Morgan Stanley Lawrence Biegelsen - Wells Fargo Securities Christopher Schott - J.P. Morgan Chas ...
J&J (JNJ) Q1 Earnings Beat Estimates, Sales Miss, MedTech Soft
Zacks Investment Research· 2024-04-16 15:56
Johnson & Johnson’s (JNJ) first-quarter 2024 earnings came in at $2.71 per share, which beat the Zacks Consensus Estimate of $2.64. Earnings rose 12.4% from the year-ago period.Adjusted earnings exclude intangible amortization and some other special items. Including these items, J&J reported first-quarter earnings of $2.20 per share against a loss of 19 cents in the year-ago quarter.Sales of this drug and medical devices giant came in at $21.38 billion, missing the Zacks Consensus Estimate of $21.40 billion ...
J&J's first quarter profits top estimates on strong cancer drug sales
Proactive Investors· 2024-04-16 15:07
About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...
Johnson & Johnson (JNJ) Reports Q1 Earnings: What Key Metrics Have to Say
Zacks Investment Research· 2024-04-16 14:31
For the quarter ended March 2024, Johnson & Johnson (JNJ) reported revenue of $21.38 billion, down 13.6% over the same period last year. EPS came in at $2.71, compared to $2.68 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $21.4 billion, representing a surprise of -0.09%. The company delivered an EPS surprise of +2.65%, with the consensus EPS estimate being $2.64.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall S ...
Johnson & Johnson Stock Slips After Mixed Q1 Earnings Report
Investopedia· 2024-04-16 14:30
Key TakeawaysJohnson & Johnson shares slipped following the release of a first-quarter earnings report that included sales figures below estimates, but better-than-expected income.The company also increased its dividend, marking 62 straight years it has done so.Johnson & Johnson narrowed its full-year guidance, projecting increases to sales and adjusted earnings per share (EPS) of about 5% and 7%, respectively. Johnson & Johnson (JNJ) posted a mixed first-quarter earnings Tuesday, and raised its dividend wh ...
Johnson & Johnson is as Cheap as it's Going to Get
MarketBeat· 2024-04-16 13:15
Key PointsJohnson & Johnson's mixed quarter revealed core strength and a widening margin. Guidance was raised with the mid-point for earnings above consensus. Analysts support this market and see it advancing at least 10%. 5 stocks we like better than Johnson & JohnsonShares of Johnson & Johnson NYSE: JNJ are as cheap as they will get. The stock is down in premarket trading following the Q1 release, but there is a bottom in play and reality to face. Trading near $145, JNJ stock is valued at less than 14X th ...
Johnson & Johnson (JNJ) Q1 Earnings Top Estimates
Zacks Investment Research· 2024-04-16 12:31
Johnson & Johnson (JNJ) came out with quarterly earnings of $2.71 per share, beating the Zacks Consensus Estimate of $2.64 per share. This compares to earnings of $2.68 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 2.65%. A quarter ago, it was expected that this world's biggest maker of health care products would post earnings of $2.27 per share when it actually produced earnings of $2.29, delivering a surprise of 0.88%. Ov ...